Stocks
Radoff-JEC Group Announces ISS’ Support of its Case for Change at Seer, Inc.
HOUSTON, July 17, 2026--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of Seer, Inc.’s (NASDAQ: SEER) ("Seer" or the "Company") outstanding common stock, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that the Company’s stockholders vote on the WHITE proxy card FOR the election of Howard H. Berman, Ph.D. and Luis E
About this update from Seer, Inc.
ISS Recommends Stockholders Vote FOR Radoff-JEC Group Nominees Howard H. Berman and Luis E. Rinaldini, WITHHOLD Support on Seer Directors Terrance McGuire, Dipchand Nishar and Nicolas Roelofs and Vote AGAINST the NOL Pill Concludes That the Board's Actions "[Raise] Questions About the Ability of the Board to Exercise Independent Oversight" of Chairman and CEO Omid Farokhzad, M.D. Radoff-JEC Group Urges Stockholders to Vote on the WHITE Proxy Card to Elect All Three of its Independent, Qualified Nominees HOUSTON, July 17, 2026 --( BUSINESS WIRE )--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of Seer, Inc.'s (NASDAQ: SEER) ("Seer" or the "Company") outstanding common stock, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that the Company's stockholders vote on the WHITE proxy card FOR the election of Howard H. Berman, Ph.D. and Luis E. Rinaldini to Seer's Board of Directors (the "Board"). ISS also recommends stockholders WITHHOLD support from incumbent directors Terrance McGuire, Dipchand Nishar, as well as Nominating and Governance Committee Chair Nicolas Roelofs, Ph.D., and vote AGAINST the ratification of the NOL pill. In its report, ISS affirmed the Radoff-JEC Group's case for urgent boardroom change, stating:1 ISS also highlighted Seer's contradictory statements and posture toward our acquisition proposals as compared to Chairman and CEO Omid Farokhzad, M.D.'s offer: